EP4112636A4 - Activateur immunitaire tumoral, son procédé de préparation et son utilisation - Google Patents

Activateur immunitaire tumoral, son procédé de préparation et son utilisation Download PDF

Info

Publication number: EP4112636A4
Authority: EP; European Patent Office
Prior art keywords: preparation; tumor immune; immune activator; activator; tumor
Prior art date: 2020-02-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21761114.4A

Other languages

German (de)

English (en)

Other versions

EP4112636A1 (fr

Inventor

Li Deng

Shuxian Chen

Xiuxia QU

Xiaohai Gong

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wuxi Plb Therapeutics Technology Ltd Co

Original Assignee

Wuxi Plb Therapeutics Technology Ltd Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-02-28

Filing date

2021-02-26

Publication date

2023-09-27

2021-02-26 Application filed by Wuxi Plb Therapeutics Technology Ltd Co filed Critical Wuxi Plb Therapeutics Technology Ltd Co

2023-01-04 Publication of EP4112636A1 publication Critical patent/EP4112636A1/fr

2023-09-27 Publication of EP4112636A4 publication Critical patent/EP4112636A4/fr

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Immunology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

EP21761114.4A 2020-02-28 2021-02-26 Activateur immunitaire tumoral, son procédé de préparation et son utilisation Pending EP4112636A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN202010129884.6A CN113318225B (zh)	2020-02-28	2020-02-28	肿瘤免疫增强剂及其制法和应用
PCT/CN2021/078264 WO2021170111A1 (fr)	2020-02-28	2021-02-26	Activateur immunitaire tumoral, son procédé de préparation et son utilisation

Publications (2)

Publication Number	Publication Date
EP4112636A1 EP4112636A1 (fr)	2023-01-04
EP4112636A4 true EP4112636A4 (fr)	2023-09-27

Family

ID=77412707

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21761114.4A Pending EP4112636A4 (fr)	2020-02-28	2021-02-26	Activateur immunitaire tumoral, son procédé de préparation et son utilisation

Country Status (7)

Country	Link
US (1)	US20230045104A1 (fr)
EP (1)	EP4112636A4 (fr)
JP (1)	JP7513303B2 (fr)
CN (1)	CN113318225B (fr)
AU (1)	AU2021226544B2 (fr)
CA (1)	CA3169907A1 (fr)
WO (1)	WO2021170111A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010037513A1 (fr) *	2008-10-01	2010-04-08	Immatics Biotechnologies Gmbh	Composition de peptides associés à une tumeur et vaccin anti-cancéreux correspondant pour traiter le glioblastome (gbm) et d'autres cancers
WO2011115483A1 (fr) *	2010-03-15	2011-09-22	Academisch Ziekenhuis Leiden H.O.D.N. Lumc	Peptides, conjugués et procédé permettant d'augmenter l'immunogénicité d'un vaccin
WO2017192924A1 (fr) *	2016-05-04	2017-11-09	Fred Hutchinson Cancer Research Center	Vaccins à base de néoantigènes à base cellulaire et leurs utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6090388A (en) *	1998-06-20	2000-07-18	United Biomedical Inc.	Peptide composition for prevention and treatment of HIV infection and immune disorders
CN100391969C (zh) *	2006-01-28	2008-06-04	中国人民解放军第三军医大学	幽门螺杆菌尿素酶B亚单位的Th表位肽、其编码DNA、疫苗及其应用
CN101954073A (zh) *	2010-09-10	2011-01-26	浙江一就生物医药有限公司	一种新型的抗肿瘤细胞疫苗及其制备方法
CN102898508B (zh) *	2011-08-12	2014-04-30	北京大学第一医院	封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
PL2812024T3 (pl) *	2012-02-09	2018-09-28	Var2 Pharmaceuticals Aps	Celowanie glikanów siarczanu chondroityny
CN105705522B (zh) *	2013-05-14	2020-09-15	上海亨臻实业有限公司	针对低免疫原性蛋白的表位疫苗及其制法和用途
CN104107428B (zh) *	2014-05-11	2016-03-02	江苏康泰生物医学技术有限公司	一种能够增强13价肺炎球菌多糖蛋白结合物免疫原性的方法
GB201419061D0 (en) *	2014-10-27	2014-12-10	Univ Birmingham	Conjugated Vaccine
CN105734014B (zh) *	2016-02-23	2019-03-26	南京融卓生物科技有限公司	一种负载广谱抗原的树突状细胞及制备方法
CN107522772B (zh) *	2017-08-07	2020-05-19	南开大学	短肽、其作为疫苗佐剂的应用及以所述短肽作为疫苗佐剂的疫苗

2020
- 2020-02-28 CN CN202010129884.6A patent/CN113318225B/zh active Active
2021
- 2021-02-26 CA CA3169907A patent/CA3169907A1/fr active Pending
- 2021-02-26 EP EP21761114.4A patent/EP4112636A4/fr active Pending
- 2021-02-26 JP JP2022552322A patent/JP7513303B2/ja active Active
- 2021-02-26 US US17/907,941 patent/US20230045104A1/en active Pending
- 2021-02-26 WO PCT/CN2021/078264 patent/WO2021170111A1/fr not_active Ceased
- 2021-02-26 AU AU2021226544A patent/AU2021226544B2/en active Active

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010037513A1 (fr) *	2008-10-01	2010-04-08	Immatics Biotechnologies Gmbh	Composition de peptides associés à une tumeur et vaccin anti-cancéreux correspondant pour traiter le glioblastome (gbm) et d'autres cancers
WO2011115483A1 (fr) *	2010-03-15	2011-09-22	Academisch Ziekenhuis Leiden H.O.D.N. Lumc	Peptides, conjugués et procédé permettant d'augmenter l'immunogénicité d'un vaccin
WO2017192924A1 (fr) *	2016-05-04	2017-11-09	Fred Hutchinson Cancer Research Center	Vaccins à base de néoantigènes à base cellulaire et leurs utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
E. A. JAMES ET AL: "Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition", INTERNATIONAL IMMUNOLOGY, vol. 19, no. 11, 6 September 2007 (2007-09-06), GB, pages 1291 - 1301, XP055587858, ISSN: 0953-8178, DOI: 10.1093/intimm/dxm099 *
RAJU R ET AL: "EPITOPES FOR HUMAN CD4+ CELLS ON DIPHTHERIA TOXIN: STRUCTURAL FEATURES OF SEQUENCE SEGMENTS FORMING EPITOPES RECOGNIZED BY MOST SUBJECTS", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-VCH, HOBOKEN, USA, vol. 25, no. 12, 1 December 1995 (1995-12-01), pages 3207 - 3214, XP000914593, ISSN: 0014-2980, DOI: 10.1002/EJI.1830251202 *
S.K. SAINI ET AL: "Novel tools to assist neoepitope targeting in personalized cancer immunotherapy", ANNALS OF ONCOLOGY, vol. 28, 1 December 2017 (2017-12-01), pages xii3 - xii10, XP055684733, DOI: 10.1093/annonc/mdx544 *
See also references of WO2021170111A1 *
ZHANG YAN ET AL: "The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma", FRONTIERS IN IMMUNOLOGY, vol. 10, 5 November 2019 (2019-11-05), Lausanne, CH, XP093075229, ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.02472 *

Also Published As

Publication number	Publication date
CN113318225B (zh)	2024-01-19
JP7513303B2 (ja)	2024-07-09
EP4112636A1 (fr)	2023-01-04
JP2023515850A (ja)	2023-04-14
AU2021226544B2 (en)	2024-07-18
CA3169907A1 (fr)	2021-09-02
US20230045104A1 (en)	2023-02-09
AU2021226544A1 (en)	2022-10-06
WO2021170111A1 (fr)	2021-09-02
CN113318225A (zh)	2021-08-31

Legal Events

Date	Code	Title	Description
2021-09-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-12-02	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-12-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-01-04	17P	Request for examination filed	Effective date: 20220928
2023-01-04	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-06-07	DAV	Request for validation of the european patent (deleted)
2023-06-07	DAX	Request for extension of the european patent (deleted)
2023-09-27	A4	Supplementary search report drawn up and despatched	Effective date: 20230830
2023-09-27	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 14/34 20060101ALI20230824BHEP Ipc: C07K 14/33 20060101ALI20230824BHEP Ipc: A61K 39/00 20060101ALI20230824BHEP Ipc: A61K 38/00 20060101ALI20230824BHEP Ipc: A61P 35/00 20060101ALI20230824BHEP Ipc: A61K 38/16 20060101ALI20230824BHEP Ipc: A61K 39/39 20060101ALI20230824BHEP Ipc: C12N 15/63 20060101ALI20230824BHEP Ipc: C12N 15/31 20060101ALI20230824BHEP Ipc: C07K 14/195 20060101AFI20230824BHEP
2026-03-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2026-04-15	17Q	First examination report despatched	Effective date: 20260317

Publication	Publication Date	Title
EP3868788A4 (fr)	2022-08-24	Anticorps multi-spécifique, procédé de préparation associé et son application
EP3822290A4 (fr)	2022-04-06	Anticorps sema4d, son procédé de préparation et son utilisation
EP4063363A4 (fr)	2023-11-29	Dérivé pyrazolo-hétéroaryl, son procédé de préparation et son utilisation médicale
EP3967687A4 (fr)	2023-01-18	Dérivé de phénylpropénylpyridine substitué, son procédé de préparation et son utilisation médicale
EP3632907A4 (fr)	2021-02-24	Dérivé de n-(azaaryl)cyclolactame-1-carboxamide, son procédé de préparation et son utilisation
EP4056177A4 (fr)	2023-01-11	Préparation de nanomicelles de cannabinoïde et son procédé de préparation
EP3822271A4 (fr)	2022-04-13	Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation médicale
EP4385989A4 (fr)	2024-12-18	Dérivé de sulfonamide, son procédé de préparation et son utilisation médicale
EP3882276A4 (fr)	2022-03-23	Anticorps bispécifique, son procédé de préparation et son utilisation
EP3925981A4 (fr)	2022-11-09	Composition catalytique mixte, catalyseur la comprenant, et procédés de préparation associés
EP3505195A4 (fr)	2020-05-06	Materiau médical régénératif, son procédé de préparation et son utilisation
EP3424924A4 (fr)	2019-08-07	Composé d'urée, son procédé de préparation et son utilisation médicale
MX344772B (es)	2017-01-06	Analogos de estilbeno y metodos para tratar cancer.
EP3903796A4 (fr)	2022-11-02	Préparation de cardiomyocytes, son procédé de préparation et son utilisation
EP4464312A4 (fr)	2025-04-09	Oléogel, son procédé de préparation et son utilisation
EP3604343A4 (fr)	2020-03-25	Protéine de fusion, son procédé de préparation et son utilisation
EP4071170A4 (fr)	2024-05-01	Composition pharmaceutique, son procédé de préparation et son utilisation
EP3502141A4 (fr)	2020-04-08	Anticorps ciblant le facteur tissulaire, son procédé de préparation et son utilisation
EP3617218A4 (fr)	2021-01-13	Conjugué dihydroartémisinine-stéroïde, son procédé de préparation et son utilisation
EP4017912A4 (fr)	2024-03-13	Charge thermoconductrice et son procédé de préparation
EP4253477A4 (fr)	2024-05-01	Composition de résine modifiée, son procédé de préparation et son utilisation
EP4349815A4 (fr)	2025-06-25	Dérivé de 7-nitro-8-hydroxyquinoléine, son procédé de préparation et utilisation médicale associée
EA201792294A1 (ru)	2018-03-30	Комбинированное лечение (варианты) с применением серибантумаба
EP3786156A4 (fr)	2022-02-23	Inhibiteur de ferroptose 10h-phénothiazine, son procédé de préparation et son utilisation
EP4400529A4 (fr)	2024-12-25	Ester de polyéther semi-aromatique, son procédé de préparation et son utilisation